Message from the CEO Thirteen is our lucky number in Reno! On March 7th, we will be opening the doors of our 13th brand new clinic, which will be our first in Reno, Nevada. An outstanding team of professionals has been hired and advanced training will be commencing over the next two to three weeks. We are …
A closer look at Spravato/Esketamine. This episode focuses on the definition of Treatment Resistant Depression and looks at whether patients must be prescribed to an antidepressant while using Spravato. Additionally, what does one do about co-occurring conditions such as anxiety, suicidal ideation, ocd, etc?
KWC featured on Fox News 10 Discussing Spravato (esketamine) We had a great time discussing the latest news about the FDA’s recommended approval of Spravato (esketamine) for adults with treatment resistant depression with FOX News 10. Physician Dr. Mark Murphy sat down with Fox News 10 correspondent Nicole Garcia, to discuss what we do at KWC …
KWC featured on Fox News 10 Discussing Spravato (esketamine) Read More »
One thing that raised the eyebrows of everybody on the clinical team here at KWC relates to the recommended dosing of Spravato. On this episode, we discuss what the recommended dosing is during the stabilization and maintenance treatment phases. Is the dosing variable from patient to patient or fixed? What are the implications of utilizing a non-variable prescription for dosing?
This episode focuses on the cost of Spravato to the provide, end user, and insurer. What are the preliminary cost estimates for Spravato (wholesale)? Can we estimate the cost to the patient? Will insurance cover the drug? How will the treatment schedule effect the cost?
THE GREATEST BREAKTHROUGH IN 30 YEARS FOR THE TREATMENT OF TREATMENT RESISTANT DEPRESSION IS SPRAVATO / ESKETAMINE! Is it really? Or are they just confirming what we have known for the last eight years? Yes, finally Johnson and Johnson has successfully received FDA approval to provide the medical community with a new ketamine metabolite …
This episode focuses on how Spravato is administered. Is intranasal delivery effective? What type of clinical environments can provide Spravato to patients? What duration of time will patients have to commit to treatment?
On February 12, 2019 the FDA advisory committee recommended approval of Spravato (esketamine) for adults with treatment resistant depression. Hallelujah! The first new therapy in 30 years for patients suffering from this affliction, or is it?
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only.
© 2023 Ketamine Wellness Centers
